Inhaled nitric oxide for preterm infants: a systematic review

Area of Science:

• Neonatal Medicine
• Respiratory Medicine
• Pediatric Critical Care

Background:

• Preterm infants often suffer from respiratory distress.
• Bronchopulmonary dysplasia (BPD) and intracranial hemorrhage (ICH) are significant morbidities in preterm infants.
• Inhaled nitric oxide (iNO) has been explored as a therapeutic agent for respiratory conditions in newborns.

Purpose of the Study:

• To evaluate the efficacy of inhaled nitric oxide in reducing mortality, BPD, ICH, or neurodevelopmental disability in preterm infants with respiratory disease.
• To analyze the impact of iNO based on different treatment timings and infant severity.

Main Methods:

• A systematic review and meta-analysis of eleven randomized controlled trials (RCTs) were conducted.
• Trials were identified through comprehensive searches of major medical databases (Medline, Embase, Healthstar, Cochrane) and conference abstracts (1985-2006).
• Studies were categorized based on iNO administration timing (early rescue, later, or routine use) and infant criteria.

Main Results:

• Early rescue iNO for severely ill preterm infants did not improve mortality or BPD rates and showed a trend towards increased severe ICH.
• Routine iNO for intubated preterm infants demonstrated a significant reduction in the combined outcome of death or BPD (RR: 0.91).
• Routine iNO in preterm infants also suggested a reduction in severe ICH or periventricular leukomalacia (RR: 0.70).

Conclusions:

• Inhaled nitric oxide as rescue therapy for critically ill preterm infants is not effective and may increase the risk of severe intracranial hemorrhage.
• Later use of iNO to prevent bronchopulmonary dysplasia lacks significant efficacy.
• Early routine administration of iNO for mildly ill preterm infants appears to decrease the risk of serious brain injury and may enhance survival rates free from BPD.